4 completed. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Sensorion: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease SENS-401 (R-Azasetron Besylate) - Hearing Loss Ototoxic | Phase 2 | Completed | Sensorion | 48 | 2022-12-30 | 2026-07-02 |
| Evaluation of the Presence of SENS-401 in the Perilymph SENS-401 (R-Azasetron Besylate) - Hearing Loss | Phase 2 | Completed | Sensorion | 28 | 2022-08-10 | 2025-04-23 |
| Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss SENS-401, Placebo Oral Tablet - Severe Sudden Sensorineural Hearing Loss | Phase 2 / Phase 3 | Completed | Sensorion | 115 | 2019-02-15 | 2023-03-01 |
| Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy SENS-111 100mg, SENS-111 200mg, Placebo Oral Tablet - Acute Unilateral Vestibulopathy (AUV) | Phase 2 | Completed | Sensorion | 107 | 2017-08-16 | 2020-10-27 |
Hearing Loss (1) · Hearing Loss, Sudden (1)
SENS-401 (3) · seliforant (1)
France (4) · Czechia (2) · Germany (2) · Israel (2) · Australia (1) · Bulgaria (1) · Canada (1) · Hungary (1) · Italy (1) · Serbia (1) · Slovakia (1) · South Korea (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)